A new drug therapy for advanced heart failure
Ended Project Grant Awarded Last action
- Award ID
- R44HL152710
- Recipient
-
Cornovus Pharmaceuticals Inc. UEI EBD9Y2Q2JW55
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,024,868
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Originally
- Funding
-
- $3,006,151.00 Federal
- $1,018,717.00 Non-federal
- Place of performance
- Farmington, CT 06032, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $50,000 | $0 | |
| Amendment | $50,000 | $50,000 | |
| Amendment | $968,717 | $0 | |
| Amendment | $968,717 | $968,717 | |
| Original award | $968,717 | $0 |
Quick answers
Who received award R44HL152710?
R44HL152710 was awarded to Cornovus Pharmaceuticals Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on July 15, 2020.
How much is award R44HL152710 worth?
$4,024,868 has been obligated on R44HL152710: $3,006,151 in federal funding and $1,018,717 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award